Navigation Links
WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO
Date:8/19/2007

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- On August 7, J. J. Finkelstein, Chief Executive Officer of RegeneRx Biopharmaceuticals (Amex: RGN) updated the investment community in an all-new interview with http://www.wallst.net. Topics covered in the interview include RegeneRx Biopharmaceuticals' clinical trials, market potential, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About RegeneRx Biopharmaceuticals:

RegeneRx, headquartered in Bethesda, Maryland, is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack.

RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical development of its drug candidates. This model is used for research and development, manufacturing, drug formulation and clinical trials, as well as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure.

For more information about this Company, please visit http://www.regenerx.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. has received two hundred eighty dollars from RegeneRx Biopharmaceuticals, Inc. as reimbursement for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)

Contact: WallSt.net

800-4-WALLST


'/>"/>
SOURCE Financial Filings Corp.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Tercica to Present at Investment Conferences
7. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
8. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
11. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):